Nimotop S (Nimodipine)

Nimodipine, the active ingredient in Nimotop S, is a calcium channel blocker presented as an oral tablet for oral use. It is used to prevent cerebral vasospasm after subarachnoid hemorrhage and to treat neurovascular disorders.

GNH USA supplies Nimotop S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine is indicated for conditions involving cerebral vasospasm and other neurovascular disorders.

- Subarachnoid hemorrhage (post‑aneurysmal): Prevention of cerebral vasospasm following hemorrhage. - Cerebral vasospasm: Dilates cerebral vessels to improve blood flow. - Neurovascular disorders: Provides neuroprotection in selected cerebrovascular conditions.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Nausea or gastrointestinal discomfort. - Flushing or warmth sensation.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure. - Bradycardia: unusually slow heart rate. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Nimodipine, clinicians should consider several precautionary measures to ensure safe use.

- Cardiovascular status: monitor blood pressure and heart rate due to possible hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Concomitant vasodilators: avoid additive blood pressure lowering effects. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Elderly patients: start at lower dose and monitor for dizziness. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nimodipine plasma levels. - Concurrent use with other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Beta‑blockers: additive effect on heart rate and blood pressure. - Diuretics: may enhance hypotensive response.